Nausea lubiprostone

Gastrointestinal adverse events reported with lubiprostone include nausea, diarrhea, abdominal distention, abdominal pain, flatulence, vomiting, loose stools, and dyspepsia. Nausea is a prominent adverse effect and may be minimized when lubiprostone is taken with food. 

Lubiprostone is a chloride channel activator that acts locally on the gut to accelerate genitourinary transit time and delay gastric emptying. It is approved for chronic idiopathic constipation in adults. The dose is 24 mg capsule twice daily with food. Lubiprostone may cause headache, diarrhea, and nausea. 

Open-label studies An open-label extension study assessed the long-term safety, tolerability and efficacy of lubiprostone in 520 patients with constipation-predominant irritable bowel syndrome. Patients were orally administered lubiprostone (8 meg) twice daily for 36 weeks. The most common adverse events were diarrhoea (11%), nausea (11%), urinary tract infection (9%), sinusitis (9%) and abdominal distention (5.8%). No serious adverse events were considered as being treatment related. Seventeen patients discontinued lubiprostone due to a treatment-related adverse event, of which diarrhoea and nausea accoxmted for 1.2% and 0.6%, respectively [9. ... 

---